LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis

PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

July 31, 2009

Conditions
Autoimmune Hepatitis
Interventions
DRUG

LCP-Tacro (tacrolimus)

LCP-Tacro(tacrolimus)tablets starting at 2 mg once daily, then adjusted to achieve and maintain target whole blood tacrolimus levels of 3 - 6 ng/mL, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.

DRUG

Azathioprine

Azathioprine tablets 50 - 100 mg (approximately 1 mg/kg) once daily, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.

Trial Locations (12)

10029

Mount Sinai Medical Center, New York

23298

Virginia Commonwealth University, Richmond

32216

Mayo Clinic - Jacksonville, Jacksonville

55455

University of Minnesota, Minneapolis

55905

Mayo Clinic, Rochester

60611

Northwestern University, Chicago

77030

St. Luke's Advanced Liver Therapies, Houston

85054

Mayo Clinic - Phoenix, Phoenix

T2N 4N1

Heritage Medical Research Clinic, Calgary

T6G 2X8

Zeildler Ledcor Centre, Edmonton

R3E 3P4

John Buhler Research Centre, University of Manitoba Health Sciences Centre, Winnipeg

B3H 2Y9

Queen Elizabeth II Health Sciences Centre, Halifax

Sponsors
All Listed Sponsors
lead

Veloxis Pharmaceuticals

INDUSTRY

NCT00608894 - LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis | Biotech Hunter | Biotech Hunter